miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma

Figure 1 miRNA array analysis of the miRNA expression patterns in patients with distinct types of hepatocellular carcinoma (n = 12). A: The top 12 miRNAs significantly dysregulated in the tumor regions of hepatocellular carcinoma (HCC) patients based on statistical results (P < 0.01); B: miR-106b expression levels in tumor regions of patients with hepatitis B virus (HBV) -associated HCC, HCV-associated HCC, and non-B/non-C HCC; C: q-RT-PCR analysis of miR-106b expression values in the tumor and adjacent non-tumor regions of patients. Fold-increases were calculated after comparing the results with the miR-106b expression levels in normal liver samples. Data represent the mean ± SD. ^aP < 0.05, ^bP < 0.001 vs HCV.